Business Wire

Adoption of New Therapy for Autoimmune Diseases to Benefit Millions of Patients in Over 100 Countries

9.7.2017 09:30 | Business Wire

Jaa

Professor Tadamitsu Kishimoto of the Osaka University, winner of the King Faisal International Prize for Medicine 2017, has stated that more than 100 countries, including Saudi Arabia, have adopted an effective biological approach in the treatment of autoimmune diseases, raising hopes for millions of people around the world who suffer from such diseases. The new treatment is significant considering that autoimmune diseases, which result from the failure of immune system cells to differentiate between the body’s tissues and cells, and alien tissues and cells, cause the body to fight against itself.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170708005001/en/

Professor Tadamitsu Kishimoto (Photo: ME NewsWire)

Professor Tadamitsu Kishimoto (Photo: ME NewsWire)

Professor Kishimoto, who was recently awarded the prestigious prize for the discovery of endogenous chemical interleukin-6’s (IL-6) pathway and its role in inflammatory and autoimmune diseases, said this while delivering a lecture organised by the King Faisal International Prize at the College of Medicine at the King Saud University in Riyadh. This lecture reflected the King Faisal International Prize’s efforts to promote the dissemination, transfer and localisation of knowledge by honouring humanitarian achievements and celebrating everything that serves people and improves their wellbeing.

A world-renowned immunologist, Professor Kishimoto has, through his research during the last 30 years, developed an IL-6 receptor-blocking antibody that has been recognized as the first approved treatment for diseases such progressive sclerosis and rheumatoid arthritis.

“The discovery of IL-6 receptor-blocking antibody has led to a major breakthrough in the treatment of autoimmune diseases. It has been approved for treatment in over 100 countries, including Saudi Arabia, Japan, the EU, and the US. Today almost one million people suffering from such diseases are being successfully treated with this antibody,” stated Kishimoto.

Besides being an immune protein, IL-6 is responsible for fever in autoimmune, infectious or non-infectious diseases, and is produced in the body wherever there is inflammation. IL-6 is implicated in a wide variety of inflammation-associated diseases, including diabetes mellitus and systemic juvenile rheumatoid arthritis.

The discovery of the antibody has not only led to the treatment of inflammatory diseases but has also paved the way for the training of several immunologists in all parts of the world, added Professor Kishimoto.

The King Faisal International Prize in Medicine has earlier been awarded to two researchers from Japan. Tetsuro Fujiwara was the first recipient when he shared the award with Bengt A. Robertson of Sweden in 1996 for research on the management of Neonatal Respiratory Distress Syndrome. Shinya Yamanaka was the second winner, sharing the prize in 2011 with James Alexander Thomson of USA. Yamanaka later won the Nobel Prize in 2012.

To know more about King Faisal International Prize, visit our website:

www.kfip.org

*Source: ME NewsWire

Contact information

for King Faisal Foundation
Hussain Abu Hajer, +966568685008
Hussain@hadathgroup.com
or
Rima Abuobaid
UAE Mob: +971509155921
KSA Mob: +966556890730
rima@hadathgroup.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33Tiedote

The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09Tiedote

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s

NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00Tiedote

NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve

Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00Tiedote

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme